ANGPTL4 and coronary artery disorder: E40K carrier status was found to be associated with a significantly reduced risk of coronary artery disease (20, 21, 27, 28), suggesting that the inactivation of ANGPTL4 may be a viable pharmacological strategy to improve plasma lipid levels and reduce the risk of coronary artery disease.